Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies and Antibody Drug Conjugates

Sanjay Nilapwar's Biography

Sanjay Nilapwar, Scientist (Development- ADC), MedImmune

Dr Sanjay Nilapwar works as a purification process scientist in Novel Molecules group of Medimmune, Gaithersburg and also part of platform ADC CMC development team. In current position, he looks after transitioning of ADC molecules from research to development and manufacturing stage, encompassing cycle 1 and 2 process and purification development, technology transfer and CMC aspects. As a In 2013 he started working for Spirogen, prior to its takeover by Medimmune, where he worked development of site-specific and stochastic PBD based conjugation at research scale, stability and analytical assay development and was instrumental in setting up scale-up ADC purification lab. He started working on protein conjugates at Piramal Lifescience by conjugating a range of therapeutic drugs including cytotoxics/radiolabeled chelates to therapeutic mAbs for Targeted therapies. He has more than 12 years of experience in protein/conjugates purification development and has published 7 papers and written couple of book chapters. Dr. Nilapwar has earned his PhD in Molecular Biology and Biophysics from UCL, London and M. Pharm in Pharmaceutical Chemistry from Mumbai University.

Sanjay Nilapwar Image

Development of Robust, Scalable Site-Specific Conjugation for Monoclonal and Bispecific mAbs: A DOE Approach

Friday, 30 September 2016 at 15:15

Add to Calendar ▼2016-09-30 15:15:002016-09-30 16:15:00Europe/LondonDevelopment of Robust, Scalable Site-Specific Conjugation for Monoclonal and Bispecific mAbs: A DOE ApproachAntibodies and Antibody Drug Conjugates in

Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonAntibodies and Antibody Drug ConjugatesAntibodies and Antibody Drug Conjugates in